Search Results

There are 1151 results for: content related to: Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy

  1. You have free access to this content
    Omalizumab for asthma in adults and children

    Intervention Review

    The Cochrane Library

    Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters and Parameswaran Nair

    Published Online : 13 JAN 2014, DOI: 10.1002/14651858.CD003559.pub4

  2. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

    Clinical & Experimental Allergy

    Volume 35, Issue 4, April 2005, Pages: 408–416, S. T. Holgate, R. Djukanović, T. Casale and J. Bousquet

    Version of Record online : 11 APR 2005, DOI: 10.1111/j.1365-2222.2005.02191.x

  3. Safety and tolerability of omalizumab

    Clinical & Experimental Allergy

    Volume 39, Issue 6, June 2009, Pages: 788–797, J. Corren, T. B. Casale, B. Lanier, R. Buhl, S. Holgate and P. Jimenez

    Version of Record online : 17 MAR 2009, DOI: 10.1111/j.1365-2222.2009.03214.x

  4. You have free access to this content
    Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria

    Journal of the European Academy of Dermatology and Venereology

    Volume 30, Issue S5, July 2016, Pages: 25–32, A. M. Giménez-Arnau, E. Toubi, A. M. Marsland and M. Maurer

    Version of Record online : 10 JUN 2016, DOI: 10.1111/jdv.13697

  5. You have free access to this content
    An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma

    Allergy

    Volume 63, Issue 6, June 2008, Pages: 670–684, S. D. Sullivan and F. Turk

    Version of Record online : 25 APR 2008, DOI: 10.1111/j.1398-9995.2008.01723.x

  6. You have free access to this content
    EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

    Allergy

    Volume 70, Issue 7, July 2015, Pages: 727–754, O. Boyman, C. Kaegi, M. Akdis, S. Bavbek, A. Bossios, A. Chatzipetrou, T. Eiwegger, D. Firinu, T. Harr, E. Knol, A. Matucci, O. Palomares, C. Schmidt-Weber, H.-U. Simon, U. C. Steiner, A. Vultaggio, C. A. Akdis and F. Spertini

    Version of Record online : 24 APR 2015, DOI: 10.1111/all.12616

  7. You have free access to this content
    Effects of omalizumab on markers of inflammation in patients with allergic asthma

    Allergy

    Volume 64, Issue 12, December 2009, Pages: 1728–1736, S. Holgate, N. Smith, M. Massanari and P. Jimenez

    Version of Record online : 15 OCT 2009, DOI: 10.1111/j.1398-9995.2009.02201.x

  8. You have full text access to this OnlineOpen article
    Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment

    Allergy

    Volume 71, Issue 9, September 2016, Pages: 1335–1344, A. Magnan, A. Bourdin, C. M. Prazma, F. C. Albers, R. G. Price, S. W. Yancey and H. Ortega

    Version of Record online : 24 MAY 2016, DOI: 10.1111/all.12914

  9. You have free access to this content
    Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR

    Allergy

    Volume 59, Issue 7, July 2004, Pages: 709–717, A. M. Vignola, M. Humbert, J. Bousquet, L-P. Boulet, S. Hedgecock, M. Blogg, H. Fox and K. Surrey

    Version of Record online : 4 JUN 2004, DOI: 10.1111/j.1398-9995.2004.00550.x

  10. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis

    Clinical & Experimental Allergy

    Volume 38, Issue 2, February 2008, Pages: 329–337, T. Nagakura, S. Ogino, K. Okubo, N. Sato, M. Takahashi and T. Ishikawa

    Version of Record online : 7 DEC 2007, DOI: 10.1111/j.1365-2222.2007.02894.x

  11. You have free access to this content
    Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

    Allergy

    Volume 66, Issue 5, May 2011, Pages: 671–678, J. Bousquet, Z. Siergiejko, E. Świebocka, M. Humbert, K. F. Rabe, N. Smith, J. Leo, C. Peckitt, R. Maykut and G. Peachey

    Version of Record online : 21 JAN 2011, DOI: 10.1111/j.1398-9995.2010.02522.x

  12. Impact of omalizumab on medical cost of childhood asthma in Japan

    Pediatrics International

    Volume 58, Issue 5, May 2016, Pages: 425–428, Hideki Yoshikawa, Mihoko Iwata, Hiroshi Matsuzaki, Rintaro Ono, Yoko Murakami, Naohiko Taba, Satoshi Honjo, Chikako Motomura and Hiroshi Odajima

    Version of Record online : 13 MAY 2016, DOI: 10.1111/ped.12936

  13. You have free access to this content
    Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE

    British Journal of Clinical Pharmacology

    Volume 72, Issue 2, August 2011, Pages: 306–320, Philip J. Lowe and Didier Renard

    Version of Record online : 11 JUL 2011, DOI: 10.1111/j.1365-2125.2011.03962.x

  14. You have free access to this content
    Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma

    British Journal of Clinical Pharmacology

    Volume 68, Issue 1, July 2009, Pages: 61–76, Philip J. Lowe, Stacey Tannenbaum, Aurelie Gautier and Pablo Jimenez

    Version of Record online : 26 FEB 2009, DOI: 10.1111/j.1365-2125.2009.03401.x

  15. You have free access to this content
    The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective

    Allergy

    Volume 65, Issue 9, September 2010, Pages: 1141–1148, J. D. Campbell, D. E. Spackman and S. D. Sullivan

    Version of Record online : 10 FEB 2010, DOI: 10.1111/j.1398-9995.2010.02336.x

  16. You have free access to this content
    A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab

    British Journal of Clinical Pharmacology

    Volume 63, Issue 5, May 2007, Pages: 548–561, Naoto Hayashi, Yuko Tsukamoto, William M. Sallas and Philip J. Lowe

    Version of Record online : 10 NOV 2006, DOI: 10.1111/j.1365-2125.2006.02803.x

  17. Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial

    Allergy

    Volume 71, Issue 8, August 2016, Pages: 1135–1144, P. Staubach, M. Metz, N. Chapman-Rothe, C. Sieder, M. Bräutigam, J. Canvin and M. Maurer

    Version of Record online : 31 MAR 2016, DOI: 10.1111/all.12870

  18. Omalizumab (Xolair) in children with seasonal allergic rhinitis: Leukotriene release as a potential in vitro parameter to monitor therapeutic effects

    Pediatric Allergy and Immunology

    Volume 18, Issue 6, September 2007, Pages: 523–527, Matthias Volkmar Kopp, Stefan Stenglein, Wolfgang Kamin, Frank Friedrichs, Andrea Von Berg, Stefan Zielen, Eckard Hamelmann, Ulrich Wahn and Joachim Kuehr

    Version of Record online : 2 AUG 2007, DOI: 10.1111/j.1399-3038.2007.00557.x

  19. You have free access to this content
    Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma

    Allergy

    Volume 59, Issue 7, July 2004, Pages: 701–708, J. G. Ayres, B. Higgins, E. R. Chilvers, G. Ayre, M. Blogg and H. Fox

    Version of Record online : 4 JUN 2004, DOI: 10.1111/j.1398-9995.2004.00533.x

  20. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients

    Arthritis & Rheumatology

    Volume 68, Issue 9, September 2016, Pages: 2274–2282, Marie Jachiet, Maxime Samson, Vincent Cottin, Jean-Emmanuel Kahn, Guillaume Le Guenno, Philippe Bonniaud, Hervé Devilliers, Laurence Bouillet, Anne Gondouin, Fatma Makhlouf, Nadine Meaux-Ruault, Helder Gil, Boris Bienvenu, André Coste, Matthieu Groh, Violaine Giraud, Stéphane Dominique, Bertrand Godeau, Xavier Puéchal, Chahera Khouatra, Marc Ruivard, Claire Le Jeunne, Luc Mouthon, Loïc Guillevin, Benjamin Terrier and for the French Vasculitis Study Group

    Version of Record online : 25 AUG 2016, DOI: 10.1002/art.39663